Neuro disorder biotech Protagenic Therapeutics prices upsized Nasdaq uplisting at $4.15 midpoint

renaissancecap...2021-04-28

Protagenic Therapeutics, an early stage biotech developing therapies for stress-related neuropsychiatric and mood disorders, raised $13 million by offering 3.2 million units at $4.15, the midpoint of ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Growmywealth
2021-04-28
Growmywealth
Like pls
- cozyli:
  done..pls reply.thanks
- Growmywealth:
  Sure
- Timtan85:
  Like n comment

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1179831996?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-04-28 10:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179831996","market":"us","top_or_hot":-1,"title":"Neuro disorder biotech Protagenic Therapeutics prices upsized Nasdaq uplisting at $4.15 midpoint","media":"renaissancecap...","content":"<div>\n<p>Protagenic Therapeutics, an early stage biotech developing therapies for stress-related neuropsychiatric and mood disorders, raised $13 million by offering 3.2 million units at $4.15, the midpoint of ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/81179/Neuro-disorder-biotech-Protagenic-Therapeutics-prices-upsized-Nasdaq-uplist\">网页链接</a>\n\n</div>\n","source":"lsy1619493174116","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuro disorder biotech Protagenic Therapeutics prices upsized Nasdaq uplisting at $4.15 midpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuro disorder biotech Protagenic Therapeutics prices upsized Nasdaq uplisting at $4.15 midpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-28 10:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/81179/Neuro-disorder-biotech-Protagenic-Therapeutics-prices-upsized-Nasdaq-uplist><strong>renaissancecap...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Protagenic Therapeutics, an early stage biotech developing therapies for stress-related neuropsychiatric and mood disorders, raised $13 million by offering 3.2 million units at $4.15, the midpoint of ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/81179/Neuro-disorder-biotech-Protagenic-Therapeutics-prices-upsized-Nasdaq-uplist\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTIX","symbol_name":"Protagenic Therapeutics Inc","start_time":0,"source_url":"https://www.renaissancecapital.com/IPO-Center/News/81179/Neuro-disorder-biotech-Protagenic-Therapeutics-prices-upsized-Nasdaq-uplist","article_id":"1179831996","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179831996","pubTimestamp":1619577019,"sourceInfo":{"source_id":"lsy1619493174116","name":"renaissancecapital"},"weMediaInfo":null,"summary":"Protagenic Therapeutics, an early stage biotech developing therapies for stress-related neuropsychia","collect":0,"end_time":0,"defaultTopTitle":"renaissancecapital.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTIX":"Protagenic Therapeutics Inc"},"translate_title":"神经紊乱生物技术主角疗法价格上涨纳斯达克上升到4.15美元中点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTIX":0.9},"content_text":"Protagenic Therapeutics, an early stage biotech developing therapies for stress-related neuropsychiatric and mood disorders, raised $13 million by offering 3.2 million units at $4.15, the midpoint of the range of $4.13 to $4.17. The company sold 0.5 million more units than anticipated. Each unit consists of one share of common stock and one warrant, exercisable at $4.98. At pricing, the company commands a fully diluted market value of $85 million.Because the company offered units with warrants attached, Protagenic Therapeutics will be excluded from Renaissance Capital's stats.\nThe company specializes in the discovery and development of therapeutics for stress-related neuropsychiatric and mood disorders, utilizing synthetic forms of endogenous brain signaling peptides that can dampen overactive stress responses. Its lead compound, PT00114, is a 41-residue peptide synthetic form of TCAP that can be administered subcutaneously, sublingually, or intra-nasally. The company intends to complete IND-enabling studies of PT00114 and enter first-in-human Phase 1/2 studies in the 3Q21.\nProtagenic Therapeutics plans to list on the Nasdaq under the symbol PTIX. Kingswood Capital Markets acted as a lead manager on the deal.","kind":null,"is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":100977351,"gmtCreate":1619577621573,"gmtModify":1634211607514,"author":{"id":"3571799401375817","authorId":"3571799401375817","name":"Growmywealth","avatar":"https://static.tigerbbs.com/44429173c7b925acb73835c4f9403a37","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3571799401375817","authorIdStr":"3571799401375817"},"htmlText":"Like pls&nbsp;","listText":"Like pls&nbsp;","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/100977351","repostId":1179831996,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4156653,"gmtCreate":1619577689427,"gmtModify":1635509332631,"authorId":3574167470846346,"author":{"id":3574167470846346,"idStr":"3574167470846346","authorId":3574167470846346,"name":"cozyli","avatar":"https://static.tigerbbs.com/509ef7c09d0624801748249c5a3e0117","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":100977351,"type":1,"supId":0,"prevId":0,"content":"done..pls reply.thanks","text":"done..pls reply.thanks","html":"done..pls reply.thanks"},{"id":4156656,"gmtCreate":1619577708441,"gmtModify":1635509332269,"authorId":3571799401375817,"author":{"id":3571799401375817,"idStr":"3571799401375817","authorId":3571799401375817,"name":"Growmywealth","avatar":"https://static.tigerbbs.com/44429173c7b925acb73835c4f9403a37","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":100977351,"type":1,"supId":4156653,"prevId":0,"content":"Sure","text":"Sure","html":"Sure"},{"id":4156721,"gmtCreate":1619577967758,"gmtModify":1635509326280,"authorId":3573460795152662,"author":{"id":3573460795152662,"idStr":"3573460795152662","authorId":3573460795152662,"name":"Timtan85","avatar":"https://static.tigerbbs.com/5ac241a703d94ceba483abb0655d0b6b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":100977351,"type":1,"supId":0,"prevId":0,"content":"Like n comment","text":"Like n comment","html":"Like n comment"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179831996"}